Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis

Table 1

Baseline characteristics of TN adenocarcinoma patients between the BIRC5 high- and low-expression groups.

Variables	BIRC5 expression level		value
	Low ()	High ()
Age, (years)			0.045
Male, (%)	40 (40.4)	56 (56.6)	0.023
Overall survival, median (IQR) (days)	704.5 (745)	658 (579)	0.427
Recurrence-free survival, median (IQR) (days)	624.5 (701)	536 (641)	0.439
Additional pharmaceutical therapy, (%)	12 (12.1)	15 (15.2)	0.534
Additional radiation therapy, (%)	14 (14.1)	26 (26.3)	0.034
Targeted molecular therapy, (%)	26 (26.3)	31 (31.3)	0.433
Partial response, (%)	1 (1.0)	2 (2.0)	0.561
Stable disease, (%)	5 (5.1)	7 (7.1)	0.551
Progressive disease, (%)	20 (20.2)	30 (30.3)	0.096
New primary tumor, (%)	6 (6.1)	1 (1.0)	0.053
Distant metastasis, (%)	10 (10.1)	20 (20.2)	0.046
Locoregional recurrence, (%)	13 (13.1)	6 (6.1)	0.091
New tumor event after initial treatment, (%)	33 (33.3)	44 (44.4)	0.109
Smoked packs per year, median (IQR),	35 (25.5)	44 (22)	0.025
TNM stage, (%)			0.194
I	64 (64.6)	52 (52.5)
II	22 (22.2)	26 (26.3)
III	9 (9.1)	18 (18.2)
IV	4 (4.0)	3 (3.0)
T stage, (%)			0.112
T1	44 (44.4)	33 (33.3)
T2	44 (44.4)	58 (58.6)
T3	10 (10.1)	6 (6.1)
T4	0 (0)	2 (2.0)
Tx	1 (1.0)	0 (0)
N stage, (%)			0.033
N0	72 (72.7)	59 (60.0)
N1	15 (15.2)	24 (24.2)
N2	8 (8.1)	15 (15.2)
N3	0 (0)	1 (1.0)
Nx	4 (4.0)	0 (0)
M stage, (%)			0.645
M0	62 (62.6)	68 (68.7)
M1	3 (3.0)	3 (3.0)
Mx	33 (33.3)	27 (27.3)
Person neoplasm cancer status, (%)			0.031
With tumor	28 (28.3)	42 (42.4)
Tumor-free	68 (68.7)	53 (53.5)
Tobacco smoking history indicator, (%)			0.630
Current smoker	9 (9.1)	12 (12.1)
Current reformed smoker for ≤15 years	17 (17.2)	12 (12.1)
Current reformed smoker for >15 years	12 (12.1)	11 (11.1)
Lifelong nonsmoker	7 (7.1)	4 (4.0)
Vital status, (%)
Living	79 (80.0)	60 (60.6)	0.003
Deceased	20 (20.2)	39 (39.4)

IQR, interquartile range.